Lilly | Pharma Marketer

Court ruling could pave way for Gemzar generics (Reuters)

Thursday, July 29th, 2010

Reuters – A decision by a U.S. appeals court could pave the way for cheaper generic forms of Eli Lilly and Co’s Gemzar cancer drug to be launched in the United States beginning in mid-November.

Posted in: headlines | 0 Comments »

Read the full story

On the Generic Gemzar Patent Fight

Wednesday, July 28th, 2010

Daniel B. Ravicher submits: Gemcitabine HCL is a chemotherapy drug for cancer treatment distributed by Eli Lilly ( LLY ) under the brand name Gemzar . In the second quarter of 2010 , Lilly made $293M from the drug, its 6th largest product

Posted in: Pharma News | 0 Comments »

Read the full story

Will MannKind’s Afrezza Succeed Where Pfizer’s Exubera Failed?

Monday, July 26th, 2010

Rockford Coscia submits: This December, Afrezza, MannKind’s ( MNKD ) inhalable insulin therapy for prandial (meal-time) management of blood glucose in diabetics, faces FDA decision. Afrezza’s path to approval is well worn and bloodied, most notably by an approval and subsequent market withdrawal of Pfizer’s ( PFE ) Exubera. Other inhalable therapies have also been attempted by such high-powered partnerships as Alkermes/Eli Lilly ( LLY ) and Aradigm/Novo Nordisk ( NVGN ); all abandoned in the wake of Exubera’s withdrawal.

Posted in: Pharma News | 0 Comments »

Read the full story

Why I Bought Call Options on Mylan

Friday, July 23rd, 2010

H.W. Daniel submits: This week, some interesting news came out from Bristol-Myers ( BMY ), Eli Lilly ( LLY ), and Johnson & Johnson ( JNJ ). This interesting news pushed me into buying call options in Mylan ( MYL ), with an expiration dating out to January 2011.

Posted in: Pharma News | 0 Comments »

Read the full story

Lilly Dismisses 340 Info Tech Employees

Thursday, July 15th, 2010

This is not a good news day for pharmaceutical industry employees. First, Sanofi-Aventis acknowledges downsizing that will affect hundreds of workers. Johnson & Johnson’s Tylenol recall scandal is claiming some 300 positions at its McNeil Consumer Healthcare unit.

Posted in: Pharma News | 0 Comments »

Read the full story

Does Eli Lilly Make for an Intelligent Investment or Intelligent Speculation Today?

Tuesday, June 29th, 2010

Bud Labitan submits Eli Lilly ( LLY ) discovers, develops, manufactures, and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries

Posted in: Pharma News | 0 Comments »

Read the full story

Eli Lilly: This Big Pharma Needs to Get Better

Monday, June 28th, 2010

Steve Alexander submits: Eli Lilly ( LLY ) is one of the largest of the “big pharmaceutical” companies, focusing especially on the clinical areas of the nervous system, endocrine system (hormones), cancer, and the cardiovascular system (heart and lungs). The firm also has a substantial veterinary drug business. Lilly’s largest and most important drug is Zyprexa, which is used to treat schizophrenia and bipolar disorders.

Posted in: Pharma News | 0 Comments »

Read the full story

Eli Lilly, Innovation And Another Cholesterol Pill

Monday, June 21st, 2010

Over the past few months, Lilly ceo John Lechleiter has made speeches in which he criticized various government policies for hindering research and development efforts ( see this ). And central to his theme has been the importance of innovation

Posted in: Pharma News | 0 Comments »

Read the full story

Mixed Results for Jointly Developed Diabetes Treatment

Thursday, June 17th, 2010

Zacks.com submits: Recently Alkermes Inc. ( ALKS ), Amylin Pharmaceuticals Inc

Posted in: Pharma News | 0 Comments »

Read the full story

Eli Lilly, Meet Eli Lilly. Topic: Outsourcing!

Friday, June 11th, 2010

Eli Lilly has been very aggressive about outsourcing their R&D work. A look at their headlines over the last few years confirms that impression. “Lilly’s Labs Go Global” (2006)

Posted in: Clinical Trials | 0 Comments »

Read the full story